Fresh From the Bench: Latest Federal Circuit Court Cases
Contributed by Schwabe Williamson & Wyatt. Originally published on Patexia; republished here as part of the LexDana archive.
CASE OF THE WEEK
Board of Regents of the University of Texas Sys. v. Boston Scientific Corp., Appeal No. 2018-1700 (Fed. Cir. Sept. 5, 2019)
This week’s case of the week involves issues relating to venue and state sovereignty. Specifically, the Federal Circuit held that state sovereignty does not grant the right to bring suit in an otherwise improper venue. As background, the Board of Regents for the University of Texas System (“UT”)—which is an arm of the State of Texas—sued Boston Scientific (“BSC”), a Delaware corporation, in the Western District of Texas for infringement of two patents relating to implantable drug-releasing fibers. Conceding that BSC was in fact a Delaware corporation with a principal place of business in Massachusetts, UT asserted that venue in Texas was proper because UT has sovereign immunity and the district court had personal jurisdiction over BSC. As to its state sovereignty assertion, UT explained that because UT is an arm of the State of Texas, it would “offend the dignity of the State to require it to pursue persons who have harmed the State outside the territory of Texas” and that the Eleventh Amendment prevents the State from being compelled to respond to counterclaims outside its territory. In its motion to dismiss or transfer venue, BSC explained that it does not own or lease property in the Western District of Texas, and that while it has 46 employees there, they maintain home offices and do not work in spaces owned, leased, or controlled by BSC. The district court determined that venue in Texas was improper because BSC does not maintain a regular and established place of business there. It also rejected UT’s arguments relating to sovereign immunity, and transferred the case to the District of Delaware.
Read more.
Written by: Scott D. Eads and Nika Aldrich, Schwabe Williamson & Wyatt
Contributor: Erin Forbes
More insights
Federal Circuit Affirms Invalidation of Patent for Lack of Enablement of Claims Directed to a Method of Treating a Patient with a Unit Dosage in Wyeth Llc v Astrazeneca Pharmaceuticals Lp
Written by : Eric Furman, Ph.D. and Ashley C. Morales Key Takeaway: Federal Circuit invalidates patent claims directed to a method for treating non-small cell lung cancer through administration of “a unit dosage” of an irreversible epidermal…
When About Becomes Indefinite Federal Circuit Provides Guidance for Life Science Patent Applications Regarding Limits of Approximation in Enviro Tech v Safe Foods
Written by : Jason J. Jardine and Kenneth O. Aruda, Ph.D. Key Takeaway: The term “about” remains useful in biotech and pharmaceutical claims, but only if the patent provides objective guidance about what the term means. Absent that guidance,…
When Any Patent Means No Patent Federal Circuit Reverses Non Specific Verdict
Written by : Brian C. Barnes and Sophia F. Zahn OLLNOVA TECHNOLOGIES LTD. v. ECOBEE TECHNOLOGIES ULC [OPINION] Before Chen , Cunningham, and Stark. Appeal from the United States District Court for the Eastern District of Texas. Summary : A verdict form…